C4 Therapeutics, Inc.
CCCC
$4.24
$0.163.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 9.11% | -0.51% | 0.31% | -12.88% | -3.44% |
| Total Depreciation and Amortization | -20.52% | 4.44% | 7.76% | 13.74% | 12.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.06% | -1.23% | 9.55% | 30.83% | 4.21% |
| Change in Net Operating Assets | -66.05% | -149.14% | -482.87% | -518.36% | -838.71% |
| Cash from Operations | 2.90% | -18.71% | -51.47% | -32.63% | -12.34% |
| Capital Expenditure | -211.31% | -272.78% | -237.22% | -73.61% | 82.39% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -191.15% | -166.50% | 84.35% | 364.57% | 221.47% |
| Cash from Investing | -191.98% | -169.03% | 83.22% | 360.05% | 233.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,443.96% | 1,104.21% | 179.79% | -92.46% | -88.74% |
| Repurchase of Common Stock | 0.83% | 0.83% | 0.52% | 7.73% | -92.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -45.70% | -45.70% | -28.27% | -27.89% | 17.63% |
| Cash from Financing | 1,419.41% | 1,085.27% | 178.80% | -92.38% | -87.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.02% | 126.02% | 126.87% | 36.98% | -82.24% |